Alnylam Pharmaceuticals (ALNY) Change in Cash (2009 - 2026)

Alnylam Pharmaceuticals' Change in Cash history runs 18 years deep, the most recent figure standing at $53.6 million for Q1 2026.

• Quarterly Change in Cash changed 0.03% year-over-year to $53.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $690.2 million (up 104.48% YoY) and the FY2025 annual result came in at $690.2 million, up 348.83% from the prior year.
• Change in Cash was $53.6 million for Q1 2026 at Alnylam Pharmaceuticals, down from $166.0 million in the prior quarter.
• Across five years, Change in Cash topped out at $497.7 million in Q3 2022 and bottomed at -$285.9 million in Q1 2022.
• A 5-year average of $52.4 million and a median of $53.6 million in 2025 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash sank 144.27% — and 2024, when it soared 2084.58%.
• Alnylam Pharmaceuticals' Change in Cash stood at -$206.8 million in 2022, then decreased by 6.52% to -$220.3 million in 2023, then jumped by 39.25% to -$133.8 million in 2024, then surged by 224.03% to $166.0 million in 2025, then slumped by 67.7% to $53.6 million in 2026.
• Business Quant data shows ALNY's Change in Cash at $53.6 million in Q1 2026, $166.0 million in Q4 2025, and $376.9 million in Q3 2025.